148 related articles for article (PubMed ID: 11173068)
1. Cardiovascular action of a cardioselective Ca(2+)channel blocker AH-1058 in conscious dogs assessed by telemetry.
Takahara A; Dohmoto H; Yoshimoto R; Sugiyama A; Hashimoto K
Eur J Pharmacol; 2001 Feb; 413(1):101-8. PubMed ID: 11173068
[TBL] [Abstract][Full Text] [Related]
2. Utilization of telemetry system to assess the cardiovascular profile of AH-1058, a new cardioselective Ca2+ channel blocker, in conscious dogs.
Takahara A; Dohmoto H; Yoshimoto R; Sugiyama A; Hashimoto K
Jpn J Pharmacol; 2001 Mar; 85(3):331-4. PubMed ID: 11325028
[TBL] [Abstract][Full Text] [Related]
3. AH-1058: a novel cardioselective Ca2+ channel blocker.
Takahara A; Sugiyama A; Yoshimoto R; Hashimoto K
Cardiovasc Drug Rev; 2001; 19(4):279-96. PubMed ID: 11830748
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiological and cardiohemodynamic effects of AH-1058, a new type calcium channel blocker, assessed by the in vivo canine model.
Takahara A; Sugiyama A; Dohmoto H; Yoshimoto R; Hashimoto K
Jpn J Pharmacol; 2000 Jun; 83(2):107-12. PubMed ID: 10928322
[TBL] [Abstract][Full Text] [Related]
5. Antiarrhythmic and cardiohemodynamic effects of a novel Ca(2+) channel blocker, AH-1058, assessed in canine arrhythmia models.
Takahara A; Sugiyama A; Dohmoto H; Yoshimoto R; Hashimoto K
Eur J Pharmacol; 2000 Jun; 398(1):107-12. PubMed ID: 10856454
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cardiovascular effects of a new calcium channel blocker AH-1058 with those of verapamil assessed in blood-perfused canine heart preparations.
Takahara A; Sugiyama A; Dohmoto H; Yoshimoto R; Hashimoto K
J Cardiovasc Pharmacol; 2000 May; 35(5):741-8. PubMed ID: 10813376
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of the utility of LVdP/dt
Pugsley MK; Guth B; Chiang AY; Doyle JM; Engwall M; Guillon JM; Hoffmann PK; Koerner JE; Mittelstadt SW; Pierson JB; Rossman EI; Sarazan DR; Parish ST
J Pharmacol Toxicol Methods; 2017; 85():1-21. PubMed ID: 28065821
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Ca(2+) channel-blocking effects of the cyproheptadine derivative AH-1058 in isolated guinea pig cardiomyocytes.
Dohmoto H; Takahara A; Uneyama H; Yoshimoto R
J Pharmacol Sci; 2003 Feb; 91(2):163-6. PubMed ID: 12686762
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced effects on cardiovascular function in pentobarbital anesthetized guinea-pigs: invasive LVP measurements versus the QA interval.
Johnson DM; Geys R; Lissens J; Guns PJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):152-9. PubMed ID: 22813982
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of CPU-23, a novel L-type calcium channel blocker with a unique molecular structure.
Dong H; Earle ML; Jiang Y; Loutzenhiser KA; Triggle CR
Br J Pharmacol; 1997 Dec; 122(7):1271-8. PubMed ID: 9421272
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of verapamil enantiomer combinations in conscious dogs.
Pagel PS; Hettrick DA; Lowe D; Gowrie PW; Kersten JR; Bosnjak ZJ; Warltier DC
Eur J Pharmacol; 1998 May; 348(2-3):213-21. PubMed ID: 9652336
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a method to correct the contractility index LVdP/dt(max) for changes in heart rate.
Markert M; Trautmann T; Groß M; Ege A; Mayer K; Guth B
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):98-105. PubMed ID: 22554385
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium.
Guth BD; Chiang AY; Doyle J; Engwall MJ; Guillon JM; Hoffmann P; Koerner J; Mittelstadt S; Ottinger S; Pierson JB; Pugsley MK; Rossman EI; Walisser J; Sarazan RD
J Pharmacol Toxicol Methods; 2015; 75():70-90. PubMed ID: 25843226
[TBL] [Abstract][Full Text] [Related]
14. QA interval as an indirect measure of cardiac contractility in the conscious telemeterised rat: model optimisation and evaluation.
Adeyemi O; Roberts S; Harris J; West H; Shome S; Dewhurst M
J Pharmacol Toxicol Methods; 2009; 60(2):159-66. PubMed ID: 19616109
[TBL] [Abstract][Full Text] [Related]
15. The effects of housing conditions on baseline cardiovascular parameters and the sensitivity to detect changes in contractility in telemetry-implanted dogs.
Sadekova N; Boudreau G; Jalbert B; Norton K
J Pharmacol Toxicol Methods; 2016; 81():60-74. PubMed ID: 27163176
[TBL] [Abstract][Full Text] [Related]
16. Translational assessment of cardiac contractility by echocardiography in the telemetered rat.
Tang HM; Ju H; Zhao S; LaDuke C; Hahn S; Glick J; Carey C; Friedrichs GS
J Pharmacol Toxicol Methods; 2016; 77():24-32. PubMed ID: 26427954
[TBL] [Abstract][Full Text] [Related]
17. In vivo antiarrhythmic profile of AP-792 assessed in different canine arrhythmia models.
Takahara A; Hirasawa A; Dohmoto H; Shoji M; Yoshimoto R; Sugiyama A; Hashimoto K
Jpn J Pharmacol; 2001 Sep; 87(1):21-6. PubMed ID: 11676194
[TBL] [Abstract][Full Text] [Related]
18. Cardiohemodynamic and electrophysiological effects of a selective EP4 receptor agonist ONO--AE1--329 in the halothane-anesthetized dogs.
Nomura H; Nakamura Y; Cao X; Honda A; Katagi J; Ohara H; Izumi-Nakaseko H; Satoh Y; Ando K; Sugiyama A
Eur J Pharmacol; 2015 Aug; 761():217-25. PubMed ID: 26073024
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of combined administration of verapamil and disopyramide in dogs.
Lee JT; Davy JM; Kates RE
J Cardiovasc Pharmacol; 1985; 7(3):501-7. PubMed ID: 2410681
[TBL] [Abstract][Full Text] [Related]
20. [The effect of atenolol on the cardiovascular system (author's transl)].
Izumi T; Nishimura T; Sakai K; Abiko Y; Hattori Y; Nakaya H; Kanno M
Nihon Yakurigaku Zasshi; 1980 Sep; 76(6):505-13. PubMed ID: 6110622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
